Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label Proxinium study in recurrent head and neck squamous cell carcinoma
ISRCTN81721411Phase 2Terminated
- Sponsor
- Viventia
- Start
- Dec 2005
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of oportuzumab monatox in head and neck squamous cell carcinoma (HNSCC), sponsored by Viventia. Primary endpoints: Safety, Tolerability and 1 more. Started Dec 2005; status: terminated.
02
Drugs
oportuzumab monatox
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN81721411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81721411.